Health Care [ 2/12 ] | Health Care Equipment & Supplies [ 23/73 ]
NASDAQ | Common Stock
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
The company was founded in 1987 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.07 Increased by +114.58% | 0.03 Increased by +133.33% |
| May 12, 25 | 0.03 Increased by +106.67% | 0.03 Increased by +15.38% |
| Mar 24, 25 | -0.11 Increased by +77.08% | 0.01 Decreased by -1.93 K% |
| Nov 8, 24 | 0.06 Increased by +105.26% | -0.20 Increased by +130.00% |
| Aug 5, 24 | -0.48 Increased by +28.36% | -0.36 Decreased by -33.33% |
| May 14, 24 | -0.45 Increased by +41.56% | -0.47 Increased by +4.26% |
| Mar 26, 24 | -0.48 Increased by +52.94% | -0.51 Increased by +5.88% |
| Nov 13, 23 | -1.14 Decreased by -23.91% | -0.52 Decreased by -119.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 24.16 M Increased by +211.05% | 2.70 M Increased by +119.63% | Increased by +11.16% Increased by +106.31% |
| Mar 31, 25 | 19.78 M Increased by +530.26% | 1.07 M Increased by +109.62% | Increased by +5.40% Increased by +101.53% |
| Dec 31, 24 | 15.10 M Increased by +2.70 K% | -3.40 M Increased by +69.49% | Decreased by -22.50% Increased by +98.91% |
| Sep 30, 24 | 9.56 M Increased by +2.10 K% | 1.86 M Increased by +109.16% | Increased by +19.50% Increased by +100.42% |
| Jun 30, 24 | 7.77 M Increased by +1.47 K% | -13.74 M Decreased by -90.79% | Decreased by -176.94% Increased by +87.84% |
| Mar 31, 24 | 3.14 M Increased by +425.80% | -11.11 M Decreased by -23.46% | Decreased by -353.97% Increased by +76.52% |
| Dec 31, 23 | 539.00 K Decreased by -15.65% | -11.14 M Increased by +7.92% | Decreased by -2.07 K% Decreased by -9.16% |
| Sep 30, 23 | 434.00 K Decreased by -52.10% | -20.34 M Decreased by -120.87% | Decreased by -4.69 K% Decreased by -361.08% |